Semax: a nootropic peptide under FDA reclassification
A peptide with a specific structural lineage, real clinical use in Russia, and a regulatory status in the US that is actively evolving.
TL;DR
- Semax is a heptapeptide derived from the ACTH(4-10) fragment — the part of adrenocorticotropic hormone associated with cognitive effects rather than cortisol production.
- Russian clinical practice has used semax for stroke rehabilitation and cognitive indications since the 1990s; FDA has not evaluated it.
- As of publication, semax is Category 2 in the US and is not available from 503A compounding pharmacies.
What it is
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic analog of ACTH(4-10), a seven-amino-acid sequence within the larger adrenocorticotropic hormone (ACTH) molecule. The ACTH(4-10) fragment was identified in the 1970s as carrying the peptide's cognitive and behavioral effects — distinct from the steroidogenic (cortisol-releasing) activity of the full ACTH molecule. Researchers at the Institute of Molecular Genetics in Moscow modified the sequence with a C-terminal Pro-Gly-Pro extension to improve metabolic stability. The resulting peptide, semax, is administered intranasally. In Russia, it has been used clinically for stroke, cognitive decline, and optic nerve conditions for several decades.
How it works
Semax's primary proposed mechanism centers on increasing levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in specific brain regions. BDNF supports the survival and differentiation of existing neurons and the growth of new ones — a process called neuroplasticity. Animal research has also shown semax influences dopaminergic and serotonergic activity. The intranasal route bypasses the blood-brain barrier more effectively than other delivery methods for some peptides. As with selank, the clinical translation of these animal and in vitro findings to humans has not been fully established through independent controlled trials.
Who asks about it
Semax surfaces in conversations about cognitive performance, focus, and neuroprotection — particularly in the context of age-related changes in mental sharpness. It also comes up in discussions of peptides for mental health support, given its neurotrophic mechanisms. The cognitive longevity angle resonates with the same audience interested in proactive brain health strategies.
What the research says
A clinical study published in Cerebrovascular Diseases (Skvortsova et al., 2006) evaluated semax in ischemic stroke patients and reported improvements in neurological outcomes compared to placebo over a 10-day treatment period. The study population was specific — acute stroke — and the findings may not generalize to healthy individuals using it for cognitive support. In vitro and rodent studies have documented BDNF upregulation and neuroprotective effects in models of oxidative stress and ischemia. A review by Dolotov et al. (2006) in the Journal of Molecular Neuroscience examined semax's neurotrophic mechanisms in more detail. No US-based Phase I/II clinical trials appear on ClinicalTrials.gov as of this writing.
What to know before considering it
Semax is not FDA-approved, and as of publication is classified as Category 2 — not available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning certain Category 2 peptides to Category 1 pending formal Federal Register rulemaking, but that process remains incomplete. Intranasal administration also carries pharmacokinetic variables — absorption rates differ by individual anatomy, mucosal health, and other factors — that make dose standardization more complicated than injectable routes.
The Halftime POV
Semax is one of the more scientifically grounded compounds in the nootropic-peptide space, with a clearer mechanistic story (BDNF/NGF upregulation) and a longer clinical history than most. The honest limitation is that the history lives in a different regulatory universe than the FDA. That matters — not because Russian research is inherently lower quality, but because independent replication in diverse populations with rigorous blinding is how the clinical field builds confidence. Semax is worth watching as the reclassification process unfolds.
Related reading:
FAQ
Q: What is Semax? A: Semax is a synthetic heptapeptide derived from the ACTH(4-10) sequence of adrenocorticotropic hormone. It was developed in Russia and has been used clinically there for ischemic stroke, cognitive impairment, and optic nerve disease. It is administered intranasally or by injection. As of April 2026, it is Category 2 in the US.
Q: What does the published research show about Semax? A: Russian clinical studies describe neuroprotective effects in ischemic stroke models and cognitive improvements in patients with neurocognitive disorders. The compound has been in clinical use in Russia for several decades. US peer-reviewed trial data is absent — the evidence base is real but not FDA-reviewed and not replicated in Western randomized controlled trials.
Q: Is Semax available through a US compounding pharmacy? A: No. As of April 2026, Semax is Category 2 under the FDA's 503A framework and cannot be dispensed by a US compounding pharmacy. The February 2026 HHS reclassification proposal may eventually change this, pending formal Federal Register notice.
Disclaimer
As of April 2026, semax is classified by the FDA as Category 2, which means it is not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- Skvortsova VI et al. "Clinical and neurophysiological effects of semax in the acute period of hemispheric stroke." — Zh Nevrol Psikhiatr, 2003
- Dolotov OV et al. "Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus." — J Mol Neurosci, 2006
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is Semax?
Semax is a synthetic heptapeptide derived from the ACTH(4-10) sequence of adrenocorticotropic hormone. It was developed in Russia and has been used clinically there for ischemic stroke, cognitive impairment, and optic nerve disease. It is administered intranasally or by injection. As of April 2026, it is Category 2 in the US.
What does the published research show about Semax?
Russian clinical studies describe neuroprotective effects in ischemic stroke models and cognitive improvements in patients with neurocognitive disorders. The compound has been in clinical use in Russia for several decades. US peer-reviewed trial data is absent — the evidence base is real but not FDA-reviewed and not replicated in Western randomized controlled trials.
Is Semax available through a US compounding pharmacy?
No. As of April 2026, Semax is Category 2 under the FDA's 503A framework and cannot be dispensed by a US compounding pharmacy. The February 2026 HHS reclassification proposal may eventually change this, pending formal Federal Register notice.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.